Navigation Links
Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
Date:10/15/2010

WALTHAM, Mass., Oct. 15 /PRNewswire/ --  Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced the UK Intellectual Property Office allowed application GB0907347.9 entitled N-(2-aminophenyl)-4-[N-(pyridine-3-YL)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B.  The patent covers the polymorph representing a preferred stable form of entinostat (SNDX-275 formerly MS-275) with key claims covering the polymorph form B and the manufacturing process by which it is derived.

This represents the first issuance for the patent application which has been filed as a Patent Cooperation Treaty (PCT) application providing a platform for additional filings worldwide including Japan, China, India, South Africa and Brazil. The patent application also has been filed in the United States, Europe, Argentina, Venezuela, Taiwan, Kuwait and Saudi Arabia. 

"We are pleased that the UK Intellectual Property Office allowed the key claims that expand the intellectual property covering entinostat with expectations for a similar outcome in the other jurisdictions in which it has been filed," said Joanna Horobin, president and chief executive officer of Syndax. "Because this important patent covers the composition of the crystalline form and the manufacturing process, it provides potential for market exclusivity in all our target indications including metastatic breast and lung cancer."  

Syndax holds 36 issued patents and pending patent applications related to the composition of matter, manufacturing and use of entinostat and HDAC inhibitors in combination with other drugs.

About EntinostatEntinostat is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. Entinostat is currently being investigated in multiple phase 2 clinical studies: in advanced breast cancer in combination with aromatase
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... WORTH, Texas , December 18, 2014 /PRNewswire/ ... a networked software application/module that is used to ... related images. RIS comprises a patient tracking and ... system. The integration of RIS with HIS and ... used for patient registration and patient scheduling, patient ...
(Date:12/19/2014)... Dec. 18, 2014 Capnia, Inc. (NASDAQ: ... of medical diagnostics based on its proprietary Sensalyze™ ... today announced financial results for the third quarter ... "Following the completion of our initial public ... maximize the recently initiated CoSense® commercial launch," said ...
(Date:12/19/2014)... and LYON, France , Dec. ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ... developing an ultra-rapid insulin, known as BioChaperone Lispro, for ... diabetes. BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology ... Lilly and Adocia will develop BioChaperone Lispro with the ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... and VANCOUVER, British Columbia, Feb. 28, 2011 ... announced today that Scott Cormack, OncoGenex,s president and chief ... on novel cancer treatments at the upcoming RBC Capital ... Treatments: Under the Radar Unique Late-Stage Opportunities ", will ...
... REDWOOD CITY, Calif., Feb. 28, 2011 At the ... Inc. (Nasdaq: CDXS ) will announce significant ... carbon dioxide emissions from coal-fired power plants.  The program ... Coal-fired power plants are major emitters of carbon dioxide, ...
Cached Medicine Technology:OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference 2Codexis Announces Carbon Capture Progress at ARPA-E Summit 2Codexis Announces Carbon Capture Progress at ARPA-E Summit 3
(Date:12/19/2014)... It’s very easy to become overwhelmed with ... put to the wayside until Christmas and the New Year ... “itch” and that burning desire to just escape it all ... journey to Telluride with a no-fuss, affordable package. Montrose Days ... the resort, and ensure that all accommodations are met. Plus, ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Sub Zero Ice ... sponsor a blood drive Sunday the 28th from 2pm-6pm at ... & Sawyer Road in Sarasota, FL. , Inquiries regarding time ... you for participating in the donating process, Sub Zero Ice ... flash frozen, custom ice cream. , About Sub Zero Ice ...
(Date:12/19/2014)... The Plantrician Project , ... events, tools and resources for healthcare professionals and ... the world’s leading online cooking school, have joined ... needs: Culinary Rx. As an online food and ... scheduled for debut spring 2015, will be designed ...
(Date:12/19/2014)... Rosa, CA (PRWEB) December 19, 2014 ... and 5x5 SuperClone Rooms. SuperCloset continues to offer indoor ... solutions. Pair one of the new SuperClone Rooms with ... professional, perpetual, and turnkey indoor hydroponic grow room setup. ... in the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... These vanadium reserves are mostly found in China, ... of vanadium were produced globally in 2013, up 11% ... 6.7% AAGR during the period from 2001 to 2013, ... largest consumer, accounted for more than 90% of total ... the chemical industry. , View Full Report at ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3
... from NewYork-Presbyterian Hospital/Weill Cornell Medical Center will present ... Association,s Annual Meeting in San Francisco, May 29 ... a urologist and professor of urology at NewYork-Presbyterian ... senior author and professor emeritus of urology at ...
... A minimally invasive technique used to destroy kidney tumors ... as surgical removal of tumors in curbing cancer recurrence ... In an article available online in the journal ... radiology at UT Southwestern Medical Center, reported the outcomes ...
... (BRONX, NY) The National Institutes of Health ... Medicine of Yeshiva University a five-year, $3.9 million grant ... in rural South Africa. The findings could alter public ... developing world. "Most cases of XDR-TB are thought ...
... ... demanding enterprise customers with VMware and Microsoft Hyper-V environments. , ... (PRWEB) June 2, 2010 -- VKernel, the ... announced today the general availability of VKernel Optimization Pack 1.4. The latest version ...
... aggressive ones, found in heaviest men, study says , WEDNESDAY, ... patients appears to be linked to patient weight, with heavier ... The finding stems from work involving more than 3,300 prostate ... surgery between 2001 and 2007 to remove a malignant prostate ...
... Risk aversion isn,t inevitable part of aging, researchers find ... says older people make less risky -- and less ... otherwise. , In some cases, older people make just ... people, researchers report. , "It,s not age, per se, ...
Cached Medicine News:Health News:NewYork-Presbyterian/Weill Cornell physician-scientists present at 2010 American Urological Meeting 2Health News:NewYork-Presbyterian/Weill Cornell physician-scientists present at 2010 American Urological Meeting 3Health News:Ablation proved as effective as traditional surgery in treating kidney cancer 2Health News:Einstein awarded NIH grant to study drug-resistant TB 2Health News:Einstein awarded NIH grant to study drug-resistant TB 3Health News:VKernel Raises Scalability and Reporting Bar with Optimization Pack 1.4 2Health News:Size of Prostate Tumor Linked to Patients' Weight 2Health News:Grandpa's Decision-Making Skills May Be Just Fine 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: